Study Urges Close Monitoring of Patients Starting Off-label Takhzyro

Study Urges Close Monitoring of Patients Starting Off-label Takhzyro

295674

Study Urges Close Monitoring of Patients Starting Off-label Takhzyro

A hereditary angioedema (HAE) patient with a rare gene mutation underwent several rounds of treatment adjustments and experienced multiple side effects while transitioning to off-label Takhzyro (lanadelumab‐flyo) over a period of 12 weeks, a study reports.  “This case highlights the importance of helping SYTL2 gene hereditary angioedema patients look for the signs of side effects of their current medications when transitioning to lanadelumab-flyo,” researchers wrote. The study, “Transition to lanadelumab‐flyo from three medications for a…

You must be logged in to read/download the full post.